Exagen Inc. (Nasdaq: XGN) reported unaudited financial results for the three and nine months ended September 30, 2026, in a Form 8-K filed on November 10, 2026. The company reported total revenue of $18.4 million for the third quarter of 2026, representing an increase of 7% compared to the same period in 2025.
Year-to-date revenue for the first nine months of 2026 was $55.7 million, up 11% compared to the $49.9 million generated in the first three quarters of 2025. The company reported a net loss of $6.3 million for the quarter, a reduction of 12% compared to the net loss of $7.1 million in the prior year. Adjusted EBITDA for the quarter was a loss of $1.9 million, an improvement of over 30% compared to the prior year.
Exagen noted that the trailing twelve-month average selling price (ASP) for its AVISE CTD test was $451 per test, an increase of $10 per test compared to the third quarter of 2025. The company ended the quarter with $28.1 million in cash and cash equivalents.
In corporate updates, Exagen presented nine abstracts at the 2026 American College of Rheumatology (ACR) Convergence Conference. The company also stated it remains on track to launch its myositis offering early in 2027.
Regarding guidance, Exagen reiterated its full-year 2026 revenue guidance of $72 million to $75 million. The company will host a webcast on December 15, 2026, at 12:00 p.m. ET to discuss its myositis solution and pipeline development.
